Primary Immune Thrombocytopenia

Hematology·MeSH: Purpura, Thrombocytopenic, Idiopathic

Prevalence

30.0 / 100K

12 drugs in development·7 companies·7 clinical trials

Drug Pipeline by Phase

Phase 3(5)

Drug	Company
hmpl-523	HUTCHMED (China) Ltd (HMDCF)
ianalumab	Merus N.V. (MRUS)
Ianalumab	Novartis AG (NVS)
tak-079	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-079	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

Phase 2(5)

Drug	Company
eltrombopag	Novartis AG (NVS)
Eltrombopag	Novartis AG (NVS)
thrombopoietin receptor agonist	Merus N.V. (MRUS)
thrombopoietin receptor agonist	Novartis AG (NVS)
thrombopoietin receptor agonist	NOVARTIS AG (NVSEF)

Phase 4(2)

Drug	Company
Efgartigimod	ARGENX SE (ARGX)
ianalumab	Novartis AG (NVS)

BioSniper tracks 12 drugs in development for Primary Immune Thrombocytopenia across 7 companies.

There are 7 clinical trials targeting Primary Immune Thrombocytopenia tracked by BioSniper.

The estimated prevalence of Primary Immune Thrombocytopenia is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.